Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment

Leuk Lymphoma. 2023 Jul-Aug;64(8):1497-1499. doi: 10.1080/10428194.2023.2220453. Epub 2023 Jun 6.

Authors

Maria Vittoria Dubbini¹, Loredana De Marco², Licia Baldi³, Luana Vignolo³, Fiorella Ilariucci¹

Affiliations

¹ Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
² Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
³ Medical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

PMID: 37282612
DOI: 10.1080/10428194.2023.2220453

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Letter

MeSH terms

Brentuximab Vedotin / adverse effects
Hodgkin Disease*
Humans
Immunoconjugates* / adverse effects
Ki-1 Antigen
Neoplasm Recurrence, Local
Steroids

Substances

Brentuximab Vedotin
Immunoconjugates
Steroids
Ki-1 Antigen